Amy Pomeroy
@amypomeroy.bsky.social
computational cancer pharmacologist at UNC | modeling clinical trials of combination therapy
Reposted by Amy Pomeroy
New paper, with Amy Pomeroy!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
now out in Blood Cancer Discovery:
doi.org/10.1158/2643...
#mathonc #lymsm #BloodCancer
1/n
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
now out in Blood Cancer Discovery:
doi.org/10.1158/2643...
#mathonc #lymsm #BloodCancer
1/n
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Abstract. Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patien...
doi.org
April 10, 2025 at 2:57 AM
New paper, with Amy Pomeroy!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
now out in Blood Cancer Discovery:
doi.org/10.1158/2643...
#mathonc #lymsm #BloodCancer
1/n
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
now out in Blood Cancer Discovery:
doi.org/10.1158/2643...
#mathonc #lymsm #BloodCancer
1/n
I am so excited to share that our new paper is out!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Abstract. Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patien...
doi.org
April 10, 2025 at 3:57 PM
I am so excited to share that our new paper is out!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
Reposted by Amy Pomeroy
An impressive result from their work - their model would have been able to predict from single treatment trials what would have happened in the combination trials
February 10, 2025 at 10:48 PM
An impressive result from their work - their model would have been able to predict from single treatment trials what would have happened in the combination trials
Reposted by Amy Pomeroy
Dr. Amy Pomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy
doi.org/10.1101/2024...
doi.org/10.1101/2024...
February 10, 2025 at 10:37 PM
Dr. Amy Pomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy
doi.org/10.1101/2024...
doi.org/10.1101/2024...